Osteoporosis treatment gap prior to femoral fracture and prevalence of pharmacological risk factors: a prospective observational study - Report - MDSpire
Clinical Report: Addressing the Treatment Deficiency for Osteoporosis Before Hip Fractures
Overview
This study evaluates the guideline concordance of osteoporosis therapy in patients admitted with hip fractures and quantifies the prevalence of medications associated with increased fall and fracture risk.
Background
Osteoporosis is a major public health concern, particularly in older adults, as it leads to severe consequences such as hip fractures, which are associated with high morbidity and mortality. Despite effective pharmacological treatments, many patients do not receive appropriate therapy following fragility fractures, particularly hip fractures.
Data Highlights
No numerical data available in the provided source material.
Key Findings
Hip fractures have a one-year mortality rate approaching 20% and increase the risk of subsequent fractures.
Austria has one of the highest incidences of hip fractures in Europe.
Current guidelines emphasize a risk-based approach to osteoporosis treatment initiation.
Medication-related risk factors, particularly fall-risk-increasing drugs (FRIDs), contribute to fracture risk in older adults.
Structured medication reviews are recommended to identify potentially inappropriate medications.
Clinical Implications
Conducting medication reviews can help identify and mitigate the risks associated with fall-risk-increasing medications.
Conclusion
The study highlights the importance of addressing medication-related risks in patients with hip fractures.
Baptist Health Orthopedic Care offers a Bone Health and Fracture Prevention Program for patients at increased risk of fracture who may benefit from early evaluation and treatment.
